GLS and lung carcinoma: For instance, the KEAPSAKE trial (Clinicaltrials.gov; NCT04265534) evaluated addition of a glutaminase inhibitor (telaglenastat) to standard-of-care immunotherapy and chemotherapy in advanced lung cancer.